medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number 2

<< Back Next >>

Ann Hepatol 2009; 8 (2)

Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats

El-Sherbiny GA, Taye A, Abdel-Raheem IT

Language: English
References: 50
Page: 134-140
PDF size: 58.27 Kb.


Text Extraction

Incidence of hepatotoxicity caused by the broad spectrum antibiotic combination amoxicillin-clavulanic acid (Co-amoxyclav) has been increasingly recognized and the mechanism of this toxicity remains undefined. On the other hand, Ursodeoxycholic acid (UDCA) has been suggested as efficient antioxidant therapy in various liver diseases. Therefore, the present study was designed to elucidate the possible role of oxidative stress in hepatotoxicity induced by Co-amoxyclav and the putative protective role of UDCA in rats. Effects of amoxicillin (Amox; 50 mg/kg, orally, 21 d) or clavulanic acid (Clav; 10 mg/kg, orally, 21 d) and their combined administration on the biochemical liver parameters, reduced glutathione (GSH), lipid peroxidation measured as hepatic malondialdehyde (MDA) levels. In addition, myeloperoxidase (MPO) activity and reactive oxygen species (ROS) production in liver homogenate were also evaluated. On the other hand, the protective effects of pretreatment with UDCA (20 mg/kg, orally, 21 d) on these parameters were also evaluated. Our results show that pretreatment with UDCA reduced the liver parameters that were enhanced by single or combined administration of Amox and/or Clav such as serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and serum bilirubin levels. Moreover, pretreatment with UDCA normalized the GSH level and inhibited the elevation in hepatic MDA concentration. The enhanced MPO activity and ROS production in liver homogenate of rats treated with Clav or Co-amoxyclav were also normalized by UDCA pretreatment. In conclusion, the present data suggest that UDCA acts as effective hepatoprotective agent against liver dysfunction caused by Co-amoxyclav and this effect is related to its antioxidant properties.


REFERENCES

  1. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1,100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232(2): 133-138.

  2. Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. Am J Med Sci 2003; 325(1): 31-33.

  3. Garcia-López M, Martinez-Blanco M, Martinez-Mir I, Palop V. Amoxicillin-clavulanic acid-related tooth discoloration in children. Pediatrics 2001; 108(3): 819-823.

  4. O’Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47(5): 717-720.

  5. Jordan T, Gonzalez M, Casado M, Suarez JF. Amoxicillin-clavulanic acid induced hepatotoxicity with progression to cirrhosis. Gastroenterol Hepatol 2002; 25(4): 240-243.

  6. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129(2): 512-521.

  7. Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990; 25(6): 774-780.

  8. Poupon RE, Eschwège E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol 1990; 11(1): 16-21.

  9. Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur J Clin Pharmacol 1991; 40(5): 473-476.

  10. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16(3): 707-714.

  11. Poupon R, Serfaty L. Ursodeoxycholic acid in chronic hepatitis C. Gut 2007; 56(12): 1652-1653.

  12. Kotb MA. Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: Review of a historical cohort. Dig Dis Sci 2008; 53(12): 3112-3118.

  13. Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid. Nippon Shokakibyo Gakkai Zasshi 1975; 72(6): 690-702.

  14. Salen G, Tint GS, Shefer S. Treatment of cholesterol gallstones with litholytic bile acids. Gastroenterol Clin North Am 1991; 20(1): 171-182.

  15. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32(6): 1196-1199.

  16. Nishio A, Keeffe EB, Ishibashi H, Gershwin EM. Diagnosis and treatment of primary biliary cirrhosis. Med Sci Monit 2000; 6(1): 181-193.

  17. Guicciardi ME, Gores GJ. Is ursodeoxycholate an antiapoptotic drug. Hepatology 1998; 28(6): 1721-1723.

  18. Lukivskaya O, Lis R, Egorov A, Naruta E, Tauschel HD, Buko VU. The protective effect of ursodeoxycholic acid in alloxan-induced diabetes. Cell Biochem Funct 2004; 22(2): 97-103.

  19. Ljubuncic P, Abu-Salach O, Bomzon A. Ursodeoxycholic acid and superoxide anion. World J Gastroenterol 2005; 11(31): 4875-4878.

  20. Lukivskaya O, Zavodnik L, Knas M, Buko V. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv Med Sci 2006; 51: 54-59.

  21. Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G, Yuksel M, Senturk O, et al. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig Dis Sci 2008; 53(4): 1071-1077.

  22. Woodnut G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumonia. Antimicrob Agents Chemother 1999; 43(1): 35-40.

  23. De Haan F, Stricker BH. Liver damage associated with the combination drug amoxicillin-clavulanic acid (Augmentin). Ned Tijdschr Geneeskd 1997; 141(26): 1298-1301.

  24. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28(1): 56-63.

  25. Eaton RH. Plasma alkaline phosphatase assay: interconversion of results by two methods. Clin Chem 1977; 23(11): 2148-2150.

  26. Merino RA, Lalive J, Parga GL. Critical analysis of bilirubinemia and diagnostic value of direct bilirubin determination by the Malloy-Evelyn method. Rev Med Chil 1968; 96(12): 794-798.

  27. Sedlák J, L’ Hanus. Changes of glutathione and protein bound SH-groups concentration in rat adrenals under acute and repeated stress. Endocrinol Exp 1982; 16(2): 103-109.

  28. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.

  29. Warren JS, Yabroff KR, Remick DG, Kunkel SL, Chensue SW, Kunkel RG, Johnson KJ, et al. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest 1989; 84(6): 1873-1882.

  30. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003; 14(8 Suppl 3): S221-6.

  31. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101(12): 2790-2799.

  32. Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007; 76: 551-573.

  33. Parks DA, Granger DN. Ischemia-reperfusion injury: a radical view. Hepatology 1988; 8(3): 680-682.

  34. Li X, Liu Y, Song L, Liu J. Responses of antioxidant systems in the hepatocytes of common carp (Cyprinus carpio L.) to the toxicity of microcystin-LR. Toxicon 2003; 42(1): 85-89.

  35. Eberle D, Clarke R, Kaplowitz N. Rapid oxidation in vitro of endogenous and exogenous glutathione in bile of rats. J Biol Chem 1981; 256: 2115-2117.

  36. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002; 64(11): 1661-1667.

  37. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 1994; 20(6): 1595-1601.

  38. Serviddio G, Pereda J, Pallardó FV, Carretero J, Borras C, Cutrin J, Vendemiale G, et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39(3): 711-720.

  39. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263(2): 537-542.

  40. Geetha A, Parameswari S. Effect of ursodeoxycholic acid on hydrogen peroxide induced lipid peroxidation in sheep liver mitochondria. Indian J Physiol Pharmacol 2002; 46(3): 343-348.

  41. Palomero J, Galán AI, Muñoz ME, Tuñón MJ, González-Gallego J, Jiménez R. Effects of aging on the susceptibility to the toxic effects of cyclosporin A in rats. Changes in liver glutathione and antioxidant enzymes. Free Radic Biol Med 2001; 30(8): 836-845.

  42. Kaur S, Kaur U, Tandon C, Dhawan V, Ganguly NK, Majumdar S. Gastropathy and defense mechanisms in common bile duct ligated portal hypertensive rats. Mol Cell Biochem 2000; 203(1-2): 79-85.

  43. Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Amoxicillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs 1981; 22(5): 337-362.

  44. Tsuji K, Kubota Y, Yamamoto S, Yanagitani K, Amoh Y, Takaoka M, Ogura M, et al. Increased neutrophil chemotaxis in obstructive jaundice: an in vitro experiment in rats. J Gastroenterol Hepatol 1999; 14(5): 457-463.

  45. Tanaka J, Yuda Y, Yamakawa T. Mechanism of superoxide generation system in indomethacin-induced gastric mucosal injury in rats. Biol Pharm Bull 2001; 24: 155-158.

  46. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48(3): 871-877.

  47. Leuschner U. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Scand J Gastroenterol Suppl 1994; 204: 40-46.

  48. Chretien Y, Poupon R, Gherardt MF, Chazouilleres O, Labbe D, Myara A, Trivin F. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut 1989; 30(8): 1110-1115.

  49. Jazrawi RP, de Caestecker JS, Goggin PM, Britten AJ, Joseph AE, Maxwell JD, Northfield TC. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106(1): 134-142.

  50. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6(3): 755-774.




2020     |     www.medigraphic.com